Serono Luveris Committee Calls For Better FDA-Sponsor Communication
Executive Summary
FDA's Reproductive Health Drugs Advisory Committee urged better communication between FDA and sponsors at the review of Serono's Luveris for infertile hypogonadotropic hypogonadal women with severe luteinizing hormone deficiency
You may also be interested in...
Serono Infertility Treatment Luveris Clears FDA
Serono will study the effect of the recombinant luteinizing hormone infertility treatment Luveris on time to clinical pregnancy as a Phase IV commitment
Serono Infertility Treatment Luveris Clears FDA
Serono will study the effect of the recombinant luteinizing hormone infertility treatment Luveris on time to clinical pregnancy as a Phase IV commitment
Serono Luveris Data Support Follicular Development Indication, Cmte. Says
Serono's Luveris data are sufficient to support a follicular development indication in infertile hypogonadotropic hypogonadal women with severe luteinizing hormone deficiency, FDA's Reproductive Health Drugs Advisory Committee said Sept. 30